Chan Cheah, MBBS

home / authors / chan-cheah-mbbs

Articles

Chan Cheah, MBBS

Dr. Cheah on the Investigation of BGB-11417 With or Without Zanubrutinib in CLL

Chan Cheah, MBBS
December 16th 2022

Chan Cheah, MBBS, discusses the investigation of BGB-11417 with or without zanubrutinib in chronic lymphocytic leukemia.

Read More

Chan Cheah, MBBS

Dr. Cheah on the Safety Profile of TG-1701 With and Without Ublituximab/Umbralisib in CLL

Chan Cheah, MBBS
October 20th 2021

Chan Cheah, MBBS, discusses the toxicity profile of TG-1701 with and without ublituximab and umbralisib in patients with chronic lymphocytic leukemia.

Read More

Dr. Cheah on the Efficacy of TG-1701 Alone and in Combination With U2 in CLL

Dr. Cheah on the Efficacy of TG-1701 Alone and in Combination With U2 in CLL

Chan Cheah, MBBS
September 19th 2021

Chan Cheah, MBBS, discusses the results of a study evaluating the efficacy and safety of TG-1701 alone and in combination with ublituximab and umbralisib in chronic lymphocytic leukemia.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data